Afimoxifene
- Generic Name
- Afimoxifene
- Drug Type
- Small Molecule
- Chemical Formula
- C26H29NO2
- CAS Number
- 68392-35-8
- Unique Ingredient Identifier
- 95K54647BZ
- Background
Afimoxifene (4-Hydroxytamoxifen, trade name TamoGel) is a new estrogen inhibitor under investigation for a variety of estrogen-dependent conditions, including cyclic breast pain and gynecomastia. TamoGel is formulated using Enhanced Hydroalcoholic Gel (EHG) Technology. This technology enables percutaneous delivery of drugs that cannot be delivered orally. It is being developed by Ascent Therapeutics.
- Indication
For the potential treatment of menstrual-cycle related mastalgia, fibrocystic breast disease, breast disease, gynecomastia and Keloid scarring.
Topical Afimoxifene in Treating Patients With Breast Cancer Who Have Undergone Radiation Therapy on One Breast
- Conditions
- Ductal Breast Carcinoma In SituInvasive Breast CarcinomaCancer Survivor
- Interventions
- First Posted Date
- 2019-07-05
- Last Posted Date
- 2023-07-13
- Lead Sponsor
- Northwestern University
- Target Recruit Count
- 156
- Registration Number
- NCT04009044
- Locations
- 🇺🇸
University of Illinois Cancer Center, Chicago, Illinois, United States
🇺🇸Northwestern University, Chicago, Illinois, United States
Afimoxifene in Reducing the Risk of Breast Cancer in Women With Mammographically Dense Breast
- Conditions
- Mammographically Dense Breast
- Interventions
- Other: Laboratory Biomarker AnalysisOther: PlaceboOther: Questionnaire Administration
- First Posted Date
- 2017-02-24
- Last Posted Date
- 2024-02-22
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 194
- Registration Number
- NCT03063619
- Locations
- 🇺🇸
Moffitt Cancer Center, Tampa, Florida, United States
🇺🇸Northwestern University, Chicago, Illinois, United States
🇺🇸Dana-Farber Cancer Institute, Boston, Massachusetts, United States
Testing an Active Form of Tamoxifen (4-hydroxytamoxifen) Delivered Through Breast Skin to Control Ductal Carcinoma in Situ (DCIS) of the Breast
- Conditions
- Estrogen Receptor PositiveDuctal Breast Carcinoma In Situ
- Interventions
- First Posted Date
- 2016-12-15
- Last Posted Date
- 2024-12-18
- Lead Sponsor
- Northwestern University
- Target Recruit Count
- 100
- Registration Number
- NCT02993159
- Locations
- 🇺🇸
Northwestern University, Chicago, Illinois, United States
🇺🇸Saint Elizabeth Medical Center South, Edgewood, Kentucky, United States
🇺🇸Mayo Clinic, Rochester, Minnesota, United States
4-Hydroxytamoxifen or Tamoxifen Citrate in Treating Women With Newly Diagnosed Ductal Breast Carcinoma in Situ
- Conditions
- Ductal Breast Carcinoma in SituEstrogen Receptor-positive Breast Cancer
- Interventions
- First Posted Date
- 2009-08-06
- Last Posted Date
- 2015-07-21
- Lead Sponsor
- Northwestern University
- Target Recruit Count
- 27
- Registration Number
- NCT00952731
- Locations
- 🇺🇸
Northwestern University, Chicago, Illinois, United States
Study of Afimoxifene Gel to Treat Cyclic Mastalgia in Premenopausal Women
- Conditions
- Cyclic Breast Pain, Cyclic Mastalgia
- First Posted Date
- 2006-01-09
- Last Posted Date
- 2023-08-16
- Lead Sponsor
- ASCEND Therapeutics
- Target Recruit Count
- 146
- Registration Number
- NCT00272714
Effect of 4-Hydroxytamoxifen Gel on Breast Density, Salivary Sex Steroids, and Quality of Life in Premenopausal Women
- Conditions
- Breast Cancer
- First Posted Date
- 2004-06-11
- Last Posted Date
- 2012-05-30
- Lead Sponsor
- Northwestern University
- Registration Number
- NCT00084344
- Locations
- 🇺🇸
Robert H. Lurie Comprehensive Cancer Center at Northwestern University, Chicago, Illinois, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.